Indication

As monotherapy for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Medicine details

Medicine name:
pemigatinib (Pemazyre)
SMC ID:
SMC2399
Pharmaceutical company
Incyte Biosciences UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
14 February 2022
SMC meeting date:
11 January 2022
Patient group submission deadline:
01 November 2021